MedPath

Troponin T and Emergency High-risk Abdominal Surgery

Conditions
Emergency Laparotomy
Inflammatory Response
Myocardial Injury
Registration Number
NCT04878159
Lead Sponsor
Copenhagen University Hospital, Hvidovre
Brief Summary

To assess whether perioperatively elevated TnT levels, using high sensitivity troponin T (hsTnT) measurements, are associated with an increased risk of postoperative mortality as well as severe postoperative complications.

Detailed Description

Cardiac Troponin T (TnT) is a cardiac-specific molecule, released into the systemic circulation following myocardial cell injury. The release of cardiac Troponins is common during critical illness and is associated with increased morbidity and mortality. The mechanisms by which TnT is released in the blood during critical illness are not fully understood, but sepsis and inflammation are primary non-cardiac conditions during which elevated TnT levels are commonly seen. Previous research has shown that 84 percent of patients admitted to ICU had at least one elevated TnT measurement perioperatively. Patients undergoing high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, are critically ill, often septic and with an acute inflammatory response and potential multiple organ system dysfunctions both prior but largely after surgery.

The hypothesis is that there is an association between elevated perioperative levels of cardiac Troponin T and mortality in patients undergoing emergency high-risk abdominal surgery.

The primary objective is to assess whether perioperatively elevated TnT levels, using high sensitivity troponin T (hsTnT) measurements, are associated with an increased risk of postoperative mortality as well as severe postoperative complications.

Patients requiring immediate emergency laparotomy or laparoscopy, including reoperations after elective gastrointestinal surgery and reoperations after previous non emergency high-risk abdominal surgery surgery, will be included in the study.

Two primary exposure measures will be investigated:

1. Peak Troponin T values ≥14 vs. Troponin T values \<14. Patients with at least one measured Troponin T value ≥14 postoperatively will be allocated to the "elevated hsTnT" group

2. Postoperative hsTnT concentration ≥14 as well as a \>50% relative increase from preoperative hsTnT concentration. Patients with hsTnT levels meeting these conditions will be allocated to the "elevated hsTnT" group hsTnT will be taken by blood samples preoperatively as well as on postoperative day 1, 2 and 3.

Primary analyses investigating the association between hsTnT and 30-day mortality (yes/no) and severe complications (yes/no) will be done using logistic regression models.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria

Adults (18 years or over) undergoing emergency laparotomy or laparoscopy for following abdominal pathology:

  • Intestinal obstruction
  • Perforated viscus
  • Intestinal ischemia
  • Intraabdominal bleeding

The above conditions include both primary surgery and re-operation after elective surgery.

Exclusion Criteria

Patients undergoing

  • Appendicectomies
  • Negative laparoscopies/laparotomies
  • Cholecystectomies
  • Simple herniotomies following incarceration without bowel resection
  • Reoperation due to fascial separation with no other abdominal pathology identified
  • Internal hernia after Roux-en-Y gastric bypass surgery
  • Subacute surgery (surgery planned within 48 h) for inflammatory bowel diseases
  • Subacute colorectal cancer surgery
  • Patients with missing hsTnT values on both postoperative day 1 and 2

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severe complication (Clavien Dindo ≥ 3)30 days
Death30 days
Secondary Outcome Measures
NameTimeMethod
Length of hospital stay30 days
Death90 days
Length of ICU stay30 days

Trial Locations

Locations (1)

Copenhagen University Hospital Hvidovre

🇩🇰

Hvidovre, Denmark

© Copyright 2025. All Rights Reserved by MedPath